The 2026 Signal Transduction and Targeted Therapy study by Deiman et al. used patient-derived iPSC-cardiomyocytes to demonstrate that antisense RNA targeting reduces PLN R14del protein aggregates and restores calcium-handling pathways via phosphoproteomics. This in vitro experimental design, not an RCT, employed cellular models without reported human sample sizes or conflicts disclosed, yet it mechanistically links aggregate clearance to reversal of disease-specific phosphorylation changes. Mainstream reports overlook how these delivery gains build on prior RNA successes like patisiran in ATTR cardiomyopathy (NEJM 2018 RCT, n=225), extending similar oligonucleotide precision to inherited dilated/arrhythmogenic forms prevalent in Dutch founder populations. The work identifies gaps in current heart-failure management by showing restored cellular function beyond symptom palliation, though translation risks remain high absent larger in vivo validation. Synthesis with a 2023 Circulation Research review on genetic cardiomyopathies underscores that such targeted reduction of mutant PLN could alter disease trajectory where beta-blockers fail, positioning Dutch centers at the forefront of precision cardiology.